C
China Pharma Holdings Inc (CPHI)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • AMEX
$0.52
-0.04 (-7.47%)
Market Cap: $22.29M
Last updated: Nov 17, 2026 at 10:59 AM ET
China Pharma Holdings Inc (CPHI) Valuation Multiples
China Pharma Holdings (CPHI) trades at 5.4x sales and 0.6x book value. Its forward P/E is 1.6x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 1.6x |
| Price to sales | 5.4x |
| Price to book | 0.6x |
| PEG | N/A |
Valuation History
Over the 5 of the 10 year ends shown that have a P/S, its P/S ranged from 0.2x in 2023 to 80.6x in 2019.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.21 | 1.3x | 0.8x |
| 2024 | $2.33 | 0.5x | 0.6x |
| 2023 | $6.05 | 0.2x | 0.9x |
| 2022 | $47.95 | N/A | 71.9x |
| 2021 | $241.30 | N/A | N/A |
| 2020 | $222.90 | N/A | N/A |
| 2019 | $120.00 | 80.6x | 191.2x |
| 2018 | $128.70 | 25.9x | 19.7x |
| 2017 | $90.00 | N/A | 68.8x |
| 2016 | $130.00 | N/A | 84.6x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CPHI
What is CPHI's forward P/E ratio?
China Pharma Holdings has a forward P/E ratio of 1.6x.
Is CPHI stock overvalued?
GNG's valuation label for CPHI is Fairly valued.
What is CPHI's price to sales ratio?
China Pharma Holdings has a price to sales ratio of 5.4x.
CPHI pages: Overview, Earnings, Financials, Valuation, Competitors